Al-Mubarak, Ali A.
Grote Beverborg, Niels
Zwartkruis, Victor
van Deutekom, Colinda
de Borst, Martin H.
Gansevoort, Ron T.
Bakker, Stephan J. L.
Touw, Daan J.
de Boer, Rudolf A.
van der Meer, Peter
Rienstra, Michiel
Bomer, Nils http://orcid.org/0000-0001-5926-6960
Funding for this research was provided by:
Dutch research council (OCENW.KLEIN.483)
Junior Scientific Masterclass-MD/PhD program of the UMCG
Pharma Nord
ZonMW (DECISION project 848090001)
Dutch Heart Foundation (DECISION project 848090001)
Cardiovascular Medical Research and Education Fund (RACE V (CVON 2014–9), RED-CVD (CVON2017-11))
Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance, CVON-AI (2018B017)))
the European Union’s Horizon 2020 research and innovation programme (EHRA-PATHS (945260))
Article History
Received: 21 November 2022
Accepted: 24 July 2023
First Online: 17 August 2023
Declarations
:
: The UMCG, which employs several of the authors has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, Vifor, and Roche. M.R. received consultancy fees from Medtronic, Arca Biopharma Inc, and Roche to the institution. The remaining authors have nothing to disclose.